Thoughts on JP Morgan Conference
There is a lot of good commentary and analysis of last week's JP Morgan Healthcare conference, most notably here, here, and here. Here are a few of our thoughts as…
Menu
Impressions from JP Morgan – Day One
In our meetings and informal discussions, there were three items we heard again and again: 1. Last year was a terrible fund raising year from a VC-backed company perspective. 2.…
More Government Involvement in Pharma Industry
The past few months have seen a number of reports describing how national governments are using policy to spur local pharmaceutical industry growth. We have already described examples from Brazil,…
Drug Development and Delivery: What’s in a name?
Our good friends at Drug Delivery Technology have, as of January, changed the name of their publication to Drug Development and Delivery. Why is this significant? We think that drug…
EMA Publishes “Biosimilar Friendly” Guidelines
The EMA has recently published guidelines for the development of monoclonal antibody-containing biosimilar products.
Backing Biosimilars
BioPharm Int'l recently published a nice overview of where the FDA debate is on biosimilars. Highlights: There is broad support for legislation which clarifies the path for biosimilars to be…
Lilly Shows Interest in Alzheimer’s Diagnostics
Today we learn that Lilly is acquiring Avid Radiopharmaceuticals: Lilly will acquire all outstanding shares of Avid for an upfront payment of $300 million, subject to adjustment based on existing cash on…
Genes are Natural, and Not Patentable
Fascinating turn of events on Friday, when the DOJ: said on Friday that human and other genes should not be eligible for patents because they are part of nature This…
Orphan Drugs & Venture Capital Backed Companies
The October, 2010 issue of Life Science Leader has an interesting article entitled Orphan Drugs: Big Pharma's Next Act? The premise is that Big Pharma is turning towards orphan drug…
Biosimilars, Champagne, and Beer
A former business development colleague of mine used to refer to some prospects as having "champagne tastes with beer wallets." His meaning was clear. It's one thing to want champagne,…